Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study

[limcheeese22]

prnewswire.com/news-release...

During 2023 International Conference, stay tuned

[park_bear]

Good catch. That little nugget is buried as a one-liner deep in the press release.

The question arises as to why did they bury that announcement in that way, and why is the exact time and date of the presentation not clear? I checked the conference website and they did not say.

[Hidden]

healthunlocked.com/cure-par...

[LeharLover62]

Thank you for sharing! Here’s the info on the data:

“Dr. Fang's presentation will cover the study designs of the current Phase 2/3 study in Alzheimer's disease and the Phase 3 study in Parkinson's disease, as well as the interim analysis of the Parkinson's Disease study that includes results from 30% of patients who have received 2 months of treatment. Dr. Fang will also show the planned development to NDA.”

[limcheeese22]

but no exact date and the time yet? At least couldn’t find

[Router_]

I read somewhere on Twitter that the presentation on pd interim results is on Thursday the 30th

[jimcaster]

Dr. Fang will present "the interim analysis of the Parkinson's Disease study that includes results from 30% of patients who have received 2 months of treatment."

As a trial participant, I have been eager to see that information, but I have been unsuccessful. Has anyone else found Dr. Fang's recent presentation?

[ZebraDoodle]

prnewswire.com/news-release...

Interim analysis for Phase 3 study of buntanetap for the treatment of early Parkinson's disease (PD): On March 31, 2023, the Company announced that it had received the results of the pre-planned blinded interim analysis conducted by a data analytics provider based on 132 patients from all cohorts collectively for which baseline and two-month data was available. As the interim analysis was conducted at two months of the six-month endpoint and only on 132 patients, it may not be indicative of the results at six months for the full patient population because as the trial progresses, clinical outcomes may materially change as patient enrollment continues and more patient data become available, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Based on the results of the interim analysis, the Company intends to proceed with the trial as planned in accordance with the previously established protocol.

[jimcaster in reply to ZebraDoodle]

Thanks for sharing this. I was hoping it might offer some interim clues regarding efficacy, but I don't think this offers much of a signal either way.

[WinnieThePoo in reply to jimcaster]

Agreed. Bigger group, double the trial duration, and it looks like they are not seeing enough for them to reduce the size of the trial planned. But neither are they cancelling or expanding it